文献速递造血干细胞移植与细胞治疗

STRIvE-02:全身给药B7-H3嵌合抗原受体T细胞治疗复发/难治性实体瘤患者的首次人体I期研究

STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors.
PubMed 文献 · J Clin Oncol · 2024-09-10

该首次人体I期研究采用标准3+3剂量递增设计,评估全身给药B7-H3 CAR T细胞在复发/难治性实体瘤年轻患者中的安全性。16例患者入组,9例接受DL1(0.5×10^6 CAR T细胞/kg,n=3)或DL2(1×10^6 CAR T细胞/kg,n=6)治疗,首次输注无剂量限制性毒性。B7-H3 CAR T细胞可耐受且抗肿瘤活性有限,无急性on-target off-tumor毒性;高水平CAR T细胞扩增可能为客观缓解所需,但宿主和肿瘤微环境因素似乎关键。

要点

  • 16例患者入组,9例接受DL1(0.5×10^6/kg,n=3)或DL2(1×10^6/kg,n=6)治疗,首次输注无剂量限制性毒性。
  • 外周血最大首次输注CAR T细胞为4.98 cells/μL(范围0-4.98 cells/μL),1例患者转移灶检出CAR T细胞与肿瘤细胞共定位。
  • 1例首次输注无客观缓解患者第二次输注后28天达PERCIST部分缓解,CAR T细胞扩增至1,590 cells/μL并伴细胞因子释放综合征和剂量限制性转氨酶升高。

核心结论

  • B7-H3 CAR T细胞可耐受,抗肿瘤活性有限,无急性on-target off-tumor毒性;高水平CAR T细胞扩增可能为客观缓解所需,但宿主和肿瘤微环境因素似乎关键。

研究设计与样本

  • 首次人体I期临床试验,采用标准3+3剂量递增设计,评估全身给药B7-H3 CAR T细胞在复发/难治性实体瘤年轻患者中的安全性。
  • 16例患者入组(范围11-24岁;中位18.5岁),9例接受DL1(0.5×10^6 CAR T细胞/kg;n=3)或DL2(1×10^6 CAR T细胞/kg;n=6)治疗。

主要发现

  • 首次输注无剂量限制性毒性。
  • 外周血最大首次输注CAR T细胞为4.98 cells/μL(范围0-4.98 cells/μL),1例患者转移灶检出CAR T细胞与肿瘤细胞共定位。
  • 1例首次输注无客观缓解患者第二次输注后28天达PERCIST部分缓解,第二次输注CAR T细胞扩增至1,590 cells/μL,伴细胞因子释放综合征和剂量限制性转氨酶升高。
  • 外周血细胞因子分析显示第二次输注前IL-21水平较第一次输注升高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: B7-H3 is an immunoregulatory protein overexpressed by many pediatric solid tumors with limited expression on critical organs, making it an attractive immunotherapy target. We present a first-in-human phase I clinical trial systemically administered B7-H3 chimeric antigen receptor (CAR) T cells for young patients with relapsed or refractory solid tumors. PATIENTS AND METHODS: Patients were enrolled onto a phase I trial to examine the safety of B7-H3-specific CARs at various dose levels (DLs) using a standard 3 + 3 dose escalation design. RESULTS: Sixteen patients (range, 11-24 years; median, 18.5 years) were enrolled, and nine were treated at DL1 (0.5 × 106 CAR T cells/kg; n = 3) or DL2 (1 × 106 CAR T cells/kg; n = 6). There were no first infusion dose-limiting toxicities. Maximum first-infusion circulating CAR T cells detected in the peripheral blood were 4.98 cells/μL (range, 0-4.98 cells/μL) with detection of CAR T cells colocalizing with tumor cells at the site of metastatic disease in one patient. Patients were eligible for subsequent infusions. An objective partial response by PERCIST criteria was observed 28 days after a second CAR T cell infusion in a patient who did not have an objective response after the first infusion. The second infusion demonstrated marked enhancement of CAR T cell expansion to 1,590 cells/μL and was accompanied by cytokine release syndrome and dose-limiting transaminitis. Detailed peripheral blood cytokine profiling revealed elevated IL-21 levels preinfusion 2 compared with infusion 1. CONCLUSION: B7-H3 CAR T cells are tolerable and demonstrate limited antitumor activity without acute on-target, off-tumor toxicity. High levels of CAR T cell expansion may be necessary to achieve objective responses, but undefined host and tumor microenvironment factors appear to be critical (ClinicalTrials.gov identifier: NCT04483778).

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Pinto N, Albert CM, Taylor MR, et al. STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors. J Clin Oncol. 2024. PMID: 39255444. doi:10.1200/JCO.23.02229

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。